Biomarin Pharmaceutical Stock Price on November 18, 2024
| BMRN Stock | USD 64.26 0.81 1.28% |
Below is the normalized historical share price chart for Biomarin Pharmaceutical extending back to July 23, 1999. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Biomarin Pharmaceutical stands at 64.26, as last reported on the 24th of November, with the highest price reaching 64.46 and the lowest price hitting 63.78 during the day.
If you're considering investing in Biomarin Stock, it is important to understand the factors that can impact its price. Biomarin Pharmaceutical secures Sharpe Ratio (or Efficiency) of -0.19, which signifies that the company had a -0.19% return per unit of risk over the last 3 months. Biomarin Pharmaceutical exposes twenty-four different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Biomarin Pharmaceutical's Mean Deviation of 1.27, risk adjusted performance of (0.14), and Standard Deviation of 2.53 to double-check the risk estimate we provide.
At this time, Biomarin Pharmaceutical's Total Stockholder Equity is very stable compared to the past year. As of the 24th of November 2024, Liabilities And Stockholders Equity is likely to grow to about 7.2 B, while Common Stock Shares Outstanding is likely to drop about 127.6 M. . At this time, Biomarin Pharmaceutical's Price Cash Flow Ratio is very stable compared to the past year. As of the 24th of November 2024, Price Fair Value is likely to grow to 3.99, while Price To Sales Ratio is likely to drop 7.11. Biomarin Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 23rd of July 1999 | 200 Day MA 80.9576 | 50 Day MA 68.2524 | Beta 0.31 |
Biomarin |
Sharpe Ratio = -0.1889
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | BMRN |
Estimated Market Risk
| 2.55 actual daily | 22 78% of assets are more volatile |
Expected Return
| -0.48 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.19 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Biomarin Pharmaceutical is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Biomarin Pharmaceutical by adding Biomarin Pharmaceutical to a well-diversified portfolio.
Price Book 2.2623 | Enterprise Value Ebitda 23.5219 | Price Sales 4.4489 | Shares Float 179.2 M | Wall Street Target Price 98.3859 |
Related Headline
Alnylam Pharmaceuticals Headline on 18th of November 2024
Alnylam shares hold Buy rating as TD Cowen notes sustained e... by investing.com
Alnylam shares hold Buy rating as TD Cowen notes sustained efficacy in interim Phase 1b results
Biomarin Pharmaceutical Valuation on November 18, 2024
It is possible to determine the worth of Biomarin Pharmaceutical on a given historical date. On November 18, 2024 Biomarin was worth 63.15 at the beginning of the trading date compared to the closed value of 61.93. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Biomarin Pharmaceutical stock. Still, in general, we apply an absolute valuation method to find Biomarin Pharmaceutical's value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Biomarin Pharmaceutical where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Biomarin Pharmaceutical's related companies.
| Open | High | Low | Close | Volume | |
| 66.05 | 66.05 | 63.22 | 63.42 | 1,687,358 | |
11/18/2024 | 63.15 | 63.52 | 61.40 | 61.93 | 2,061,275 |
| 61.57 | 62.03 | 61.15 | 61.97 | 1,893,980 |
| Backtest Biomarin Pharmaceutical | | | Biomarin Pharmaceutical History | | | Biomarin Pharmaceutical Valuation | Previous | Next |
Biomarin Pharmaceutical Trading Date Momentum on November 18, 2024
| On November 19 2024 Biomarin Pharmaceutical was traded for 61.97 at the closing time. The top price for the day was 62.03 and the lowest listed price was 61.15 . The trading volume for the day was 1.9 M. The trading history from November 19, 2024 was a factor to the next trading day price boost. The overall trading delta against the next closing price was 0.06% . The overall trading delta against the current closing price is 3.15% . |
Biomarin Pharmaceutical Fundamentals Correlations and Trends
By evaluating Biomarin Pharmaceutical's financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Biomarin Pharmaceutical's main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Biomarin financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Biomarin Pharmaceutical Stock history
Biomarin Pharmaceutical investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Biomarin is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Biomarin Pharmaceutical will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Biomarin Pharmaceutical stock prices may prove useful in developing a viable investing in Biomarin Pharmaceutical
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 191.6 M | 127.6 M | |
| Net Income Applicable To Common Shares | 162.8 M | 170.9 M |
Biomarin Pharmaceutical Quarterly Net Working Capital |
|
Biomarin Pharmaceutical Stock Technical Analysis
Biomarin Pharmaceutical technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
Biomarin Pharmaceutical Period Price Range
Low | November 24, 2024
| High |
0.00 | 0.00 |
Biomarin Pharmaceutical cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Biomarin Pharmaceutical November 24, 2024 Market Strength
Market strength indicators help investors to evaluate how Biomarin Pharmaceutical stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Biomarin Pharmaceutical shares will generate the highest return on investment. By undertsting and applying Biomarin Pharmaceutical stock market strength indicators, traders can identify Biomarin Pharmaceutical entry and exit signals to maximize returns
Biomarin Pharmaceutical Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Biomarin Pharmaceutical's price direction in advance. Along with the technical and fundamental analysis of Biomarin Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Biomarin to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | (0.14) | |||
| Jensen Alpha | (0.54) | |||
| Total Risk Alpha | (0.88) | |||
| Treynor Ratio | (1.12) |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomarin Pharmaceutical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomarin Pharmaceutical. If investors know Biomarin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomarin Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.607 | Earnings Share 1.66 | Revenue Per Share 14.529 | Quarterly Revenue Growth 0.283 | Return On Assets 0.03 |
The market value of Biomarin Pharmaceutical is measured differently than its book value, which is the value of Biomarin that is recorded on the company's balance sheet. Investors also form their own opinion of Biomarin Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biomarin Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomarin Pharmaceutical's market value can be influenced by many factors that don't directly affect Biomarin Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biomarin Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomarin Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomarin Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.